Regentys and Cook Partnering on Ongoing Development of Ulcerative Colitis Therapy

Regentys and Cook Partnering on Ongoing Development of Ulcerative Colitis Therapy
Regentys and Cook Biotech are teaming up to continue developing a treatment for the inflammatory bowel disease ulcerative colitis. Under the agreement, Cook will direct the development of Regentys’ ECMH Rectal Solution, or extracellular matrix hydrogel, which Regentys plans to start clinical trials on in 2018. Cook will also manufacture the therapy. “We have been working with

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *